Remedee Labs

To improve the quality of life of the 1.5 billion people worldwide suffering from chronic pain, Remedee Labs has developed and patented the first individual endorphin stimulator based on millimetre waves. This innovative bracelet is connected, easy to use, and helps stimulate the body’s naturel painkillers to provide long-term relief.

However, improving the quality of life of chronic pain patients requires an integrated approach that addresses all aspects of a person’s well-being. Therefore, Remedee Labs has also developed a comprehensive service around the bracelet that includes personalized support from health coaches, a digital service platform, and real-life data to attest to the solution’s effectiveness.

Generali, a leading insurance company, has recognized the potential of Remedee Lab’s solution and became a strategic partner of the start-up by taking a stake in its capital in 2022. Together, they have initiated three concrete projects, including testing the solution with Generali employees, offering the solution to 300,000 beneficiaries of the Health and Provident social action, and combining Remedee Lab’s medical data and Generali’s insurance data to demonstrate the reduction in claims allowed by the solution.

In France, at least 12 million people suffer from chronic pain, and 70% of them do not receive appropriate treatment, severly impacting their quality of life. Remedee Labs’ solution offers hope for those who have been failed by traditional treatments and can improve their quality of life in the long term.